Advice
following a full submission:
aprepitant (Emend) as part of combination therapy is not recommended for use within NHS Scotland for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The aprepitant regimen showed a significant difference compared to the standard regimen in terms of the primary end-point of complete response for the acute phase only. No superiority for the aprepitant regimen could be demonstrated for the prevention of nausea.
The economic case for aprepitant in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy has not been demonstrated.
Download detailed advice57KB (PDF)
Medicine details
- Medicine name:
- aprepitant (Emend)
- SMC ID:
- 242/06
- Indication:
- Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy
- Pharmaceutical company
- MSD
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 March 2006